Drug Trial Radar · NCT03638830
Safety and Efficacy Study of Ftortiazinon in the Treatment of Patients With Complicated Urinary Tract Infections Caused by P. Aeruginosa
Last checked: Nov 19, 2026Latest source record: Jun 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
777
Actual
Start
Oct 17, 2018
Primary completion
Nov 23, 2022
Study completion Nov 23, 2022
Sponsor
- Lead sponsor
- Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian FederationAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Acellena Contract Drug Research and Development
- First posted
- Aug 20, 2018
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is planned to evaluate the safety and efficacy of the drug Ftortiazinon in combination with the drug Maxipime® in comparison with placebo in combination with the drug Maxipime® in the treatment of hospitalized adult patients with complicated urinary tract infections caused by P. aeruginosa.
Conditions
- Patients With Complicated Urinary Tract Infections Caused by P. Aeruginosa
- Pseudomonas Aeruginosa
- Pseudomonas Infections
- Urinary Tract Infections
Interventions
Ftortiazinon (tablets 300 mg) 1/2 dose +placebo+ MaxipimDrug
Ftortiazinon tablets 300 mg (FSBI "N.F. Gamaleya NRCEM" of the Ministry of Health of the Russian Federation)+placebo
Ftortiazinon (tablets 300 mg) full dose + MaxipimDrug
Ftortiazinon tablets 300 mg (FSBI "N.F. Gamaleya NRCEM" of the Ministry of Health of the Russian Federation)
placebo+MaxipimOther
placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- clinical cure and microbiological eradicationTime frame: through the whole study, an average of 90 days
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
Baltic Medicine
Saint Petersburg, Russia
Scientific and Research Center "Eco-Safety"
Saint Petersburg, Russia
Vsevolozhsk Clinical Interdistrict Hospital
Vsevolozhsk, Russia
Road Clinical Hospital of Open Joint Stock Company "Russian Railways
Saint Petersburg, Sankt-Peterburg, Russia
St. Petersburg state budgetary institution of health care " City hospital № 26"
Saint Petersburg, Sankt-Peterburg, Russia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.